Search Protocols under revision. Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsProtocol groupIndolent LymphomasDiseaseNHL, B-Cell Type, Malt LymphomaSubgroupICD10C85.9C88.4-MeSHLymphoma, B-Cell, Marginal ZoneSequenceIELSG-19 trial: CHLO6, MALT lymphoma, C1 (PID2568) -|- CHLO6, C2-5 (PID2569)RITU375/CHLO6, MALT Marginal Zone B-NHL, C1 (PID1971) -|- C2-5 (PID1974)Antineoplastic therapySubstanceChlorambucilCladribineLenalidomideRituximabSubstanceChlorambucilCladribineLenalidomideRituximabSubstanceChlorambucilCladribineLenalidomideRituximabSubstanceChlorambucilCladribineLenalidomideRituximabNo. Substances12 RadiotherapySupportive therapySubstanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDimetindenPantoprazoleParacetamolPrednisoloneSubstanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDimetindenPantoprazoleParacetamolPrednisoloneSubstanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDimetindenPantoprazoleParacetamolPrednisoloneSubstanceAcetylsalicylic acidAciclovirBalanced Crystalloid SolutionCotrimoxazoleDimetindenPantoprazoleParacetamolPrednisoloneNo. Substances234Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseConsolidationInductionTherapy intentiondisease controlpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaIncrease AminotransferasesInfectionsInfusion ReactionLeukopeniaLymphopeniaMucositisNeutropeniaPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorConconi AJäger G Kiesewetter BZucca EDiseaseExtranodales Marginalzonen-B-NHL MALT Typ, Erst- und ZweitlinieMALT-Lymphom, auch gastrisches, neu diagnostiziert oder nach lokaler TherapieMALT-Lymphom, ECOG 0-2MALT-Lymphom; Hp-negativ, wenn MALT-Lymphom des Magens; 18-80 J.Marginalzonen-B-NHL MALT TypOriginClinical Division of Oncology, Department of Internal Medicine I, University Vienna, Vienna, AustriaKarl-Franzens University of Graz, Graz, AustriaOncology Institute of Southern Switzerland, Bellinzona, IELSG-19 trialOncology Institute of Southern Switzerland, Bellinzona, IELSG-19 TrialOncology Institute of Southern Switzerland, Division Medical Oncology, Bellinzona, SchweizProtocols in Revision 7 protocols foundChlorambucil 6, MALT lymphoma, cycle 1 (PID2568 V1.0)Chlorambucil 6, MALT lymphoma, cycle 2-5 (PID2569 V1.0)Cladribine 0.12, MALT Lymphoma (PID3000 V1.0)Lenalidomide 25, MALT lymphoma (PID2999 V1.0)Rituximab 375 / Chlorambucil 6, MALT Lymphoma, cycle 1 (PID1971 V1.1)Rituximab 375 / Chlorambucil 6, MALT Lymphoma, cycle 2-5 (PID1974 V1.1)Rituximab 375, MALT Lymphoma (PID353 V1.1)
